Merck & Co’s Clesrovimab Has Beyfortus Hill To Climb In RSV

 
• By Elizabeth Cairns

Full data from Merck & Co’s Phase IIb/III trial of its novel RSV antibody suggest that it will have to fight hard against Sanofi/AstraZeneca’s leader.

Portrait of asian parent hands holding newborn baby
Beyfortus is approved for newborns and toddlers in their second RSV season • Source: Shutterstock

More from Clinical Trials

More from Therapy Areas